Agios Soars 14% after FDA Grants Priority Review to Mitapivat with Nov. 1 Deadline
AGIO•Agios shares jumped over 14% after the FDA accepted its supplemental application for mitapivat in sickle cell disease and granted Priority Review with a November 1 decision date. Approval relies on a confirmatory Phase III trial next year, despite the drug missing its primary endpoint for pain crisis reduction.
1. FDA Grants Priority Review
The FDA accepted Agios’s supplemental application for mitapivat in sickle cell disease and assigned Priority Review status, setting a November 1 decision date for a final verdict.
2. Clinical Data Considerations
Mitapivat missed its primary endpoint for reducing sickle cell pain crises in pivotal data submissions, although FDA’s accelerated approval pathway suggests confidence in the strength of the overall dataset.
3. Market Reaction and Outlook
Shares jumped over 14%, reaching a seven-month high on the FDA decision; full regulatory approval hinges on a confirmatory Phase III trial expected next year.
